Positron Corporation announced the approval of their Nuclear Regulatory Commission (NRC) manufacturing and distribution license amendment for the company's radiopharmaceutical manufacturing facility in Crown Point, Indiana. The company received its pharmacy license from the Indiana Board of Pharmacy in December 2011, which served as a precursor to the NRC amendment and recent approval, allowing Positron to manufacture and distribute radiochemicals and radiopharmaceuticals throughout the United States. The company is currently producing Indium 111 Oxyquinoline for customer evaluation and commercial sale with plans to process additional radioisotopes for medical use.